Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1090
Medha A. Bhat, N. M. Hoskatte
Bhat et al. : Anti-cancer Activity of Andrographis lineata var. lawii The major objective of this investigation was to evaluate the cytotoxic activity of Andrographis lineata Wall. ex Nees var. lawii C.B. Clarke leaf methanol extract on cancer cell lines. In vitro cytotoxicity of Andrographis lineata leaf extract was evaluated against A375 (melanoma), A549 (lung), HCT116 (colon), HeLa (cervix), HepG2 (hepatoma), Jurkat cells (T-cell acute lymphoblastic leukemia), MCF7 (breast cancer), PA1 (ovary), PC3 (prostate) and U87MG (Glioblastoma) cancer cell lines. Andrographis lineata leaf extract showed cytotoxicity activity against all cell lines, however, optimum cytotoxicity was observed against the ovarian cancer cell line (IC50=39.7 µg/ml) cell line. Cell cycle and terminal deoxynucleotidyl transferase dUTP end labeling assays confirmed the cytotoxic activity of Andrographis lineata leaf extract. Reverse phase-high performance liquid chromatography analysis was performed to recognize the active ingredient in the Andrographis lineata leaf extract and the results reveal that andrographolide was the major component. This investigation is the first report of the anticancer activity of Andrographis lineata leaf extract.
{"title":"Cytotoxic Activity of Andrographis lineata Wall. ex Nees: An In Vitro study","authors":"Medha A. Bhat, N. M. Hoskatte","doi":"10.36468/pharmaceutical-sciences.1090","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1090","url":null,"abstract":"Bhat et al. : Anti-cancer Activity of Andrographis lineata var. lawii The major objective of this investigation was to evaluate the cytotoxic activity of Andrographis lineata Wall. ex Nees var. lawii C.B. Clarke leaf methanol extract on cancer cell lines. In vitro cytotoxicity of Andrographis lineata leaf extract was evaluated against A375 (melanoma), A549 (lung), HCT116 (colon), HeLa (cervix), HepG2 (hepatoma), Jurkat cells (T-cell acute lymphoblastic leukemia), MCF7 (breast cancer), PA1 (ovary), PC3 (prostate) and U87MG (Glioblastoma) cancer cell lines. Andrographis lineata leaf extract showed cytotoxicity activity against all cell lines, however, optimum cytotoxicity was observed against the ovarian cancer cell line (IC50=39.7 µg/ml) cell line. Cell cycle and terminal deoxynucleotidyl transferase dUTP end labeling assays confirmed the cytotoxic activity of Andrographis lineata leaf extract. Reverse phase-high performance liquid chromatography analysis was performed to recognize the active ingredient in the Andrographis lineata leaf extract and the results reveal that andrographolide was the major component. This investigation is the first report of the anticancer activity of Andrographis lineata leaf extract.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1126
X. Liu, J-J Xie, Jingfang Zhu
Baicalein has anti-tumor effect and participates in multi-channel regulation mechanism. However, the mechanism of baicalein action has not been fully clarified in cervical cancer. Tumor protein D52, circ_0007364 and microRNA-665 expression were determined by quantitative reverse transcription-polymerase chain reaction. Tumor protein D52 and apoptosis-related proteins were detected by Western blot. Cell proliferation was measured via methyl thiazolyl tetrazolium, 5-ethynyl-2'-deoxyuridine and colony formation assays. The associations among microRNA-655, circ_0007364 and tumor protein D52 were determined by dual luciferase report assay. Cell invasion and apoptosis were assessed by Transwell assay and flow cytometry. The function experiments were carried out in vivo and in vitro . Baicalein significantly decreased circ_0007364 and tumor protein D52 expression and increased microRNA-665 expression in cervical cancer cell samples. Circ_0007364 or tumor protein D52 introduction and microRNA-665 down regulation weakened the suppressive effects of baicalein in cervical cancer cells. Moreover, circ_0007364 functioned by binding to microRNA-665 to regulate tumor protein D52 and affect cellular process in cervical cancer. Our study showed that baicalein inhibited cervical cancer cell growth via regulating circ_0007364/microRNA-665/tumor protein D52 axis, further understanding the anticancer mechanism of baicalein and contributing to find more effective anticancer drug components for cervical cancer.
{"title":"Baicalein Suppressed Cervical Cancer Tumourogenesis by Modulating circ_0007364/microRNA-665/Tumor Protein D52 Axis","authors":"X. Liu, J-J Xie, Jingfang Zhu","doi":"10.36468/pharmaceutical-sciences.1126","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1126","url":null,"abstract":"Baicalein has anti-tumor effect and participates in multi-channel regulation mechanism. However, the mechanism of baicalein action has not been fully clarified in cervical cancer. Tumor protein D52, circ_0007364 and microRNA-665 expression were determined by quantitative reverse transcription-polymerase chain reaction. Tumor protein D52 and apoptosis-related proteins were detected by Western blot. Cell proliferation was measured via methyl thiazolyl tetrazolium, 5-ethynyl-2'-deoxyuridine and colony formation assays. The associations among microRNA-655, circ_0007364 and tumor protein D52 were determined by dual luciferase report assay. Cell invasion and apoptosis were assessed by Transwell assay and flow cytometry. The function experiments were carried out in vivo and in vitro . Baicalein significantly decreased circ_0007364 and tumor protein D52 expression and increased microRNA-665 expression in cervical cancer cell samples. Circ_0007364 or tumor protein D52 introduction and microRNA-665 down regulation weakened the suppressive effects of baicalein in cervical cancer cells. Moreover, circ_0007364 functioned by binding to microRNA-665 to regulate tumor protein D52 and affect cellular process in cervical cancer. Our study showed that baicalein inhibited cervical cancer cell growth via regulating circ_0007364/microRNA-665/tumor protein D52 axis, further understanding the anticancer mechanism of baicalein and contributing to find more effective anticancer drug components for cervical cancer.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69606766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1141
C. Ponnam, G. N. Challa, S. R. Yarraguntla
Ponnam et al. : Stability Indicating Ultraviolet Spectrophotometric Method for Flurbiprofen An efficient, rapid, sensitive, validated stability-indicating ultraviolet spectrophotometric method was developed for flurbiprofen in eye drops. Methanol was employed as the solvent in this proposed process, and detection was carried out at a wavelength of 248 nm. The validation parameters linearity, limit of detection and limit of quantitation, accuracy, precision and specificity were all the subject of experiments according to International Council on Harmonisation guidelines. The stability of flurbiprofen was examined under acidic, alkaline, thermal, and photolytic conditions. The kinetics in the concentration range of 2-10 ug/ml were defined as linear with a correlation value of 0.992. The percentage of relative standard deviation for both intra-day and inter-day accuracy was under less than 2 % and 99.6 %-100.4 % of the drug was retrieved from the study. The system was able to identify variations related to stress conditions although the stress condition of degradation products hadn't been determined. The proposed approach can be employed as a stability indicating method for flurbiprofen screening in conventional pharmaceutical analysis of eye drops with a significant level of linearity, accuracy and precision. The method was found to be both affordable and convenient. This method can therefore be used to study flurbiprofen stress degradation behaviour in small industries without access to sophisticated equipment.
{"title":"Quantification of Flurbiprofen in Eye Drops by Stability Indicating Ultraviolet Spectrophotometric Method","authors":"C. Ponnam, G. N. Challa, S. R. Yarraguntla","doi":"10.36468/pharmaceutical-sciences.1141","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1141","url":null,"abstract":"Ponnam et al. : Stability Indicating Ultraviolet Spectrophotometric Method for Flurbiprofen An efficient, rapid, sensitive, validated stability-indicating ultraviolet spectrophotometric method was developed for flurbiprofen in eye drops. Methanol was employed as the solvent in this proposed process, and detection was carried out at a wavelength of 248 nm. The validation parameters linearity, limit of detection and limit of quantitation, accuracy, precision and specificity were all the subject of experiments according to International Council on Harmonisation guidelines. The stability of flurbiprofen was examined under acidic, alkaline, thermal, and photolytic conditions. The kinetics in the concentration range of 2-10 ug/ml were defined as linear with a correlation value of 0.992. The percentage of relative standard deviation for both intra-day and inter-day accuracy was under less than 2 % and 99.6 %-100.4 % of the drug was retrieved from the study. The system was able to identify variations related to stress conditions although the stress condition of degradation products hadn't been determined. The proposed approach can be employed as a stability indicating method for flurbiprofen screening in conventional pharmaceutical analysis of eye drops with a significant level of linearity, accuracy and precision. The method was found to be both affordable and convenient. This method can therefore be used to study flurbiprofen stress degradation behaviour in small industries without access to sophisticated equipment.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69607469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.690
Xiaofang Cai, S. Jiang, Jiana Chen, Xiujuan Cai, W. L. Wang, J. Huang, J. H. Zhang
:
：
{"title":"Efficacy and Adverse Events of Clopidogrel and Ticagrelor in Patients with Cytochrome P450 2C19 Gene Deletion","authors":"Xiaofang Cai, S. Jiang, Jiana Chen, Xiujuan Cai, W. L. Wang, J. Huang, J. H. Zhang","doi":"10.36468/pharmaceutical-sciences.spl.690","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.690","url":null,"abstract":":","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
By comparing 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser and carbon dioxide laser therapy only, to explore the therapeutic effect of 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser on perianal and anal canal condyloma acuminatum. A total of 74 patients with perianal and anal canal condyloma acuminatum who were admitted to our hospital from January 2021 to December 2021 were selected as the research objects. They were randomly assigned to the observation group and the control group, with 37 cases in each group. The observation group was treated with 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser and the control group was treated with carbon dioxide laser therapy. Both groups were treated once a week for 3 w. The therapeutic effect, recurrence rate and adverse reactions were compared between the two groups. The cure rate of condyloma acuminatum in the observation group was 86.48 %, which was higher than 54.05 % in the control group, with statistical significance (p<0.05). After follow-up, it was found that the recurrence rate of the observation group (13.51 %) was significantly lower than that of the control group (43.24 %), with statistical significance (p<0.05). The incidence of superficial scar and perianal pain in the observation group was 27.03 % and 21.62 % respectively, which was not significantly different from 35.14 % and 29.73 % in the control group. 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser in the treatment of perianal and anal canal condyloma acuminatum has the advantages of good curative effect and low recurrence rate, which is worthy of clinical promotion.
{"title":"Effect of 5-Aminolevulinic Acid Photodynamic Therapy Combined with Carbon dioxide Laser on Condyloma Acuminatum","authors":"Xiaolei Xie, Huajie Zhong, Shunli Tang, Yuan-Hong Wu, Xu Xu, Cong Zhu","doi":"10.36468/pharmaceutical-sciences.spl.681","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.681","url":null,"abstract":"By comparing 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser and carbon dioxide laser therapy only, to explore the therapeutic effect of 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser on perianal and anal canal condyloma acuminatum. A total of 74 patients with perianal and anal canal condyloma acuminatum who were admitted to our hospital from January 2021 to December 2021 were selected as the research objects. They were randomly assigned to the observation group and the control group, with 37 cases in each group. The observation group was treated with 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser and the control group was treated with carbon dioxide laser therapy. Both groups were treated once a week for 3 w. The therapeutic effect, recurrence rate and adverse reactions were compared between the two groups. The cure rate of condyloma acuminatum in the observation group was 86.48 %, which was higher than 54.05 % in the control group, with statistical significance (p<0.05). After follow-up, it was found that the recurrence rate of the observation group (13.51 %) was significantly lower than that of the control group (43.24 %), with statistical significance (p<0.05). The incidence of superficial scar and perianal pain in the observation group was 27.03 % and 21.62 % respectively, which was not significantly different from 35.14 % and 29.73 % in the control group. 5-aminolevulinic acid photodynamic therapy combined with carbon dioxide laser in the treatment of perianal and anal canal condyloma acuminatum has the advantages of good curative effect and low recurrence rate, which is worthy of clinical promotion.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.686
Yongjun Zeng, Biwei Zhan, Jingjing Liu
Zeng et
曾等
{"title":"Intraoperative Target-Controlled Infusion of Etomidate versus Propofol for General Anesthesia in Laparoscopic Cholecystectomy","authors":"Yongjun Zeng, Biwei Zhan, Jingjing Liu","doi":"10.36468/pharmaceutical-sciences.spl.686","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.686","url":null,"abstract":"Zeng et","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.629
J. Y. Zhou, L. Wei, Y. Xi, M. Hu, Jian Li, Qianqian Tang, Fangfang Chen, Jingwei Zhang
{"title":"Basement Membrane-Related Long Non-Coding RNA Signature Predicts the Prognosis of Breast Cancer","authors":"J. Y. Zhou, L. Wei, Y. Xi, M. Hu, Jian Li, Qianqian Tang, Fangfang Chen, Jingwei Zhang","doi":"10.36468/pharmaceutical-sciences.spl.629","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.629","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.630
Qian Zhang, Ze Xin Guo, Jing Zhang, D. Yang, P. Jiang, J. Cao, S. Li
{"title":"Effect of Trichostatin A on Bleomycin Induced Pulmonary Fibrosis in Mice and its Mechanism","authors":"Qian Zhang, Ze Xin Guo, Jing Zhang, D. Yang, P. Jiang, J. Cao, S. Li","doi":"10.36468/pharmaceutical-sciences.spl.630","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.630","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1161
B. Shekhany, F. Ozer, E. Aytar, S. W. Bradosty, M. U. Boyraz, A. O. Gurol, F. K. Shaikh, F. Suzergoz
{"title":"Anticancer Effects of Heterocyclic Schiff Base Ligands and Their Metal Complexes on Leukemia Cells","authors":"B. Shekhany, F. Ozer, E. Aytar, S. W. Bradosty, M. U. Boyraz, A. O. Gurol, F. K. Shaikh, F. Suzergoz","doi":"10.36468/pharmaceutical-sciences.1161","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1161","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135400279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1162
M. M. Desai, Anna Pratima G. Nikalje
{"title":"Development and Validation of Stability-indicating High-Performance Liquid Chromatography Method for Estimation of Organic Impurities of Carvedilol from Bulk and its Dosage Form","authors":"M. M. Desai, Anna Pratima G. Nikalje","doi":"10.36468/pharmaceutical-sciences.1162","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1162","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135401429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：